Rates of prostate-specific antigen testing in general practice in England and Wales in asymptomatic and symptomatic patients: A cross-sectional study

BJU International

Volumn 94, Issue 1, 2004, Pages 51-56

  Melia, Jane ^a   Moss, Sue ^a   Johns, Louise ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

England; Mass screening; Primary health care; Prostate specific antigen; Prostatic neoplasms; PSA; Wales

Indexed keywords

ARTICLE; CANCER RISK; CANCER SCREENING; CONTROLLED STUDY; DIAGNOSTIC VALUE; GENERAL PRACTICE; HEALTH SERVICE; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; MEDICAL RECORD; PRIORITY JOURNAL; PROSTATE CARCINOMA; SOCIAL ISOLATION; UNITED KINGDOM;

ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; CROSS-SECTIONAL STUDIES; ENGLAND; FAMILY PRACTICE; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; SOCIOECONOMIC FACTORS; WALES;

EID: 2642551798     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-4096.2004.04832.x     Document Type: Article

References (15)

1. De Koning HJ, Auvinen A, Berenguer SA et al. Large-scale randomized prostate cancer screening trials: program performances in the European Randomized Screening for Prostate Cancer trial and the Prostate, Lung, Colorectal and Ovary cancer trial. Int J Cancer 2002; 97: 237-44
2. Chamberlain J, Melia J, Moss S, Brown J. Report prepared for the Health Technology Assessment Panel of the NHS Executive on the diagnosis, management, treatment and costs of prostate cancer in England and Wales. Br J Urol 1997; 79: 1-32
3. Melia J, Moss S. Survey of the rate of PSA testing in general practice. Br J Cancer 2001; 85: 656-7
4. Ritchie A, Bates T, Gillatt D et al. The who and why of PSA - a survey of PSA requests in the South West of England. UroOncology 2001; 1: 237-42
5. Toussi H, Williams C, Giles M, Srinivasan V, Evans CM. PSA requesting: screening for prostate cancer is happening. BJU Int 2000; 85 (Suppl 5): 4
6. Milford Ward A, Catto J, Hamdy FC. Prostate specific antigen: biology, biochemistry and available commercial assays. Ann Clin Biochem 2001; 38: 633-51
7. Townsend P, Phillimore P, Beattie A. Health and Deprivation. Inequality and the North. London: Croom-Helm 1988
8. Etzioni R, Berry KM, Legler JM, Shaw P. Prostate-specific antigen testing black and white men: an analysis of Medicare claims from 1991 to 1998. Urology 2002; 59: 251-5
9. Nijs HG, Tordoir DM, Schuurman JH, Kirkels WJ, Schroder FH. Randomised trial of prostate cancer screening in The Netherlands: assessment of acceptance and motives for attendance. J Med Screening 1997; 4: 102-6
10. Grulich AE, Swerdlow AJ, Head J, Marmot MG. Cancer mortality in African and Caribbean migrants to England and Wales. Br J Cancer 1992; 66: 905-11
11. Gavin A, McCarron P, Middleton RJ et al. Evidence of prostate cancer screening in a UK region. BJU Int 2004; 93: 730-4
12. Donovan JL. Screening for prostate cancer in the UK. BMJ 2001; 323: 763-4
13. Singh KG. Demand for prostate specific antigen testing in primary care. Can the demand for PSA testing in primary care be managed? BMJ 2002; 2: 547
14. Parkinson MC, Bott SR, Montironi R, Melia J. Screening for prostatic cancer and its evolution within Britain. J Pathol 2002; 197: 139-42
15. Lu-Yao G, Albertsen PC, Stanford JL, Stukel T, Walker-Corkery E, Barry MJ. Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut. BMJ 2002; 325: 1-6